GEN Exclusives

More »

GEN News Highlights

More »
Sep 19, 2006

Survival Impact of Biomarker Identified in Phase III Trial of Melanoma Drug

  • Genta presented the results of a collaborative study by Genta and the Melanoma Group of the European Organization for the Research and Treatment of Cancer. The results confirmed the strong relationship between patient survival and a biomarker that was prospectively studied in the randomized Phase III trial of Genasense® (oblimersen sodium) injection in patients with advanced melanoma.

    Genta says the Genasense data derives from the largest randomized controlled trial ever conducted in patients with advanced melanoma. In this trial, 771 patients were randomly assigned to receive chemotherapy with dacarbazine alone or in combination with Genasense. The results of this trial showed that multiple outcomes, including overall survival, progression-free survival, overall response, and durable response, were strongly associated with blood levels of an enzyme known as LDH, a biomarker that was a prospectively defined stratification factor.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?